• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Maravai LifeSciences Holdings Inc.

    6/10/24 4:29:20 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRVI alert in real time by email
    SC 13G 1 p24-2084sc13g.htm MARAVAI LIFESCIENCES HOLDINGS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    Maravai LifeSciences Holdings, Inc.

    (Name of Issuer)
     

    Class A Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    56600D107

    (CUSIP Number)
     

    June 7, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 56600D10713GPage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,481,050 shares of Class A common stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,481,050 shares of Class A common stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,481,050 shares of Class A common stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.4%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 56600D10713GPage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,481,050 shares of Class A common stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,481,050 shares of Class A common stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,481,050 shares of Class A common stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.4%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 56600D10713GPage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Europe (London) LLP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,165,965 shares of Class A common stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,165,965 shares of Class A common stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,165,965 shares of Class A common stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.6%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 56600D10713GPage 5 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    6,647,015 shares of class A common stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    6,647,015 shares of class A common stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,647,015 shares of class A common stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 56600D10713GPage 6 of 8 Pages

     

     

    Item 1(a). Name of Issuer.
       
      Maravai LifeSciences Holdings, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
       
      10770 Wateridge Circle, Suite 200, San Diego, California 92121.

     

    Item 2(a). Name of Person Filing.
       
     

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of Class A common stock, par value $0.01 per share (“Class A Common Stock”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Class A Common Stock held by an investment fund managed by Point72 Asset Management; (iii) Point72 Europe (London) LLP (“Point72 Europe (London)”) with respect to Class A Common Stock held by an investment fund it manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Class A Common Stock beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Point72 Europe (London).

       
     

    Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Europe (London), and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

     

    Item 2(b). Address of Principal Business Office.
       
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Point72 Europe (London) is 8 St. James’s Square, London, United Kingdom, SW1Y 4JU.

     

    Item 2(c). Place of Organization.
       
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Point72 Europe (London) is a limited liability partnership incorporated in England and Wales. Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
       
      Class A Common Stock, par value $0.01 per share.

     

    Item 2(e). CUSIP Number.
       
      56600D107

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
       
      Not applicable.

     

     

    CUSIP No. 56600D10713GPage 7 of 8 Pages

     

     

    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on June 7, 2024.

     

    Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Europe (London), and Mr. Cohen own directly no Class A Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Point72 Europe (London) maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Point72 Europe (London). The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Class A Common Stock reported herein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      See Item 2(a).

     

       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

       
    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 56600D10713GPage 8 of 8 Pages

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: June 10, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
     

    Title: Authorized Person

     

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

     

    POINT72 EUROPE (LONDON) LLP

     

      By:  /s/ Jason M. Colombo
     

    Name: Jason M. Colombo

    Title: Authorized Person

     

      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

    Get the next $MRVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRVI

    DatePrice TargetRatingAnalyst
    2/26/2025$9.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/19/2024Neutral
    Guggenheim
    12/5/2024$4.25Neutral → Sell
    Goldman
    11/14/2024Peer Perform
    Wolfe Research
    11/8/2024Outperform → Mkt Perform
    William Blair
    8/28/2024$10.00Overweight
    Wells Fargo
    8/13/2024$11.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    4/10/2024$15.00Buy
    Craig Hallum
    More analyst ratings

    $MRVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology

      Quantoom's customers can now access TriLink's CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and ma

      6/3/25 10:00:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    SEC Filings

    See more
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      6/9/25 8:40:50 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Maravai LifeSciences Holdings Inc.

      SCHEDULE 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      5/29/25 5:24:04 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      5/28/25 5:26:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deford John A bought $100,625 worth of shares (17,500 units at $5.75), increasing direct ownership by 33% to 70,046 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/14/24 4:32:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Hull Carl bought $987,000 worth of shares (175,000 units at $5.64) (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/12/24 4:59:43 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marker Luke Joseph was granted 89,139 shares, increasing direct ownership by 182% to 138,055 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:09 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gray Susannah was granted 89,139 shares, increasing direct ownership by 110% to 169,907 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Daverman Benjamin James was granted 89,139 shares, increasing direct ownership by 182% to 138,055 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:28 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maravai Life Sciences downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously

      2/26/25 7:15:06 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Maravai Life Sciences

      Guggenheim initiated coverage of Maravai Life Sciences with a rating of Neutral

      12/19/24 8:13:54 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Life Sciences downgraded by Goldman with a new price target

      Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25

      12/5/24 7:46:04 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciencesReleases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2

      5/21/25 4:05:00 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Financials

    Live finance-specific insights

    See more
    • Maravai Lifesciences Reports First Quarter 2025 Financial Results

      SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance. "Our first quarter revenue exceeded our guidance range, an

      5/12/25 4:06:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.

      5/1/25 7:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne

      3/18/25 4:05:56 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/14/24 7:49:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 4:48:49 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 9:30:19 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care